Register here.
Join the Gaucher Community Alliance for a webinar to learn about the data from the venglustat clinical trial in type 3 Gaucher patients. During this session, Dr. Pramod Mistry will provide an overview of the design and key findings from a Phase 3 clinical study, which evaluated an investigational oral treatment called venglustat in adults and teenagers living with type 3 Gaucher disease. This webinar is intended to help patients and families better understand ongoing research efforts in the type 3 neuronopathic community.
This educational program is sponsored by Sanofi. Venglustat is an investigational treatment and has not been approved by the FDA or any other regulatory authority. The information presented is not intended as medical advice. Please consult your physician regarding your individual medical condition and treatment options.
*Closed caption translation services available.
Presented By Pramod Mistry, MBBS, PhD, MA, MD
Professor of Medicine (Digestive Diseases) and of Pediatrics (Gastroenterology)
Professor of Cellular & Molecular Physiology
Director of Yale Lysosomal Disease Center and Gaucher Disease Treatment Center
Dr. Pramod Mistry is a physician-scientist and Professor of Medicine at Yale School of Medicine who directs the Yale Gaucher Center for Lysosomal Diseases. For over 30 years, he has dedicated his career to caring for and researching rare inherited diseases, particularly Gaucher disease. Dr. Mistry has helped develop and test new treatments that have dramatically improved patients’ lives and leads international registries tracking thousands of patients to understand disease progression and treatment response. He is ranked among the top three world experts in Gaucher disease globally and has discovered important connections between rare diseases and more common conditions like Parkinson’s disease and cancer. Through his work, Dr. Mistry has ensured that patients around the world, including children in underserved regions, can access life-changing therapies. His research bridges laboratory science with patient care, and he has trained the next generation of physicians while publishing over 100 influential research papers that advance our understanding of rare diseases.
